Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine

辉瑞-BioNTech BNT162b2疫苗的先天性和适应性免疫机制

阅读:1
作者:Chunfeng Li ,Audrey Lee ,Lilit Grigoryan ,Prabhu S Arunachalam ,Madeleine K D Scott ,Meera Trisal ,Florian Wimmers ,Mrinmoy Sanyal ,Payton A Weidenbacher ,Yupeng Feng ,Julia Z Adamska ,Erika Valore ,Yanli Wang ,Rohit Verma ,Noah Reis ,Diane Dunham ,Ruth O'Hara ,Helen Park ,Wei Luo ,Alexander D Gitlin ,Peter Kim ,Purvesh Khatri ,Kari C Nadeau ,Bali Pulendran

Abstract

Despite the success of the BNT162b2 mRNA vaccine, the immunological mechanisms that underlie its efficacy are poorly understood. Here we analyzed the innate and adaptive responses to BNT162b2 in mice, and show that immunization stimulated potent antibody and antigen-specific T cell responses, as well as strikingly enhanced innate responses after secondary immunization, which was concurrent with enhanced serum interferon (IFN)-γ levels 1 d following secondary immunization. Notably, we found that natural killer cells and CD8+ T cells in the draining lymph nodes are the major producers of this circulating IFN-γ. Analysis of knockout mice revealed that induction of antibody and T cell responses to BNT162b2 was not dependent on signaling via Toll-like receptors 2, 3, 4, 5 and 7 nor inflammasome activation, nor the necroptosis or pyroptosis cell death pathways. Rather, the CD8+ T cell response induced by BNT162b2 was dependent on type I interferon-dependent MDA5 signaling. These results provide insights into the molecular mechanisms by which the BNT162b2 vaccine stimulates immune responses.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。